Defendant DANIEL V.T. CATENACCI was a gastrointestinal. medical oncologist, an associate professor of medicine, and the director of the. gastrointestinal oncology program at a university medical center in Chicago, Illinois. CATENACCI also served as one of the lead physicians and primary field investigators. Before Phase 2 study results were announced publicly, Daniel Catenacci bought 8,743 shares in Five Prime and sold them for a $134,000 profit. シカゴ大学. シカゴ大学 （シカゴだいがく、 University of Chicago 、略称 UChicago ）は、 アメリカ合衆国 ・ イリノイ州 シカゴ にある研究型 私立大学 。. 設立当初から 研究 に重点が置かれ、 ノーベル賞 受賞者を 100名輩出 しており世界で最も評価が高い大学の In November 2020, Dr. Catenacci used material, non-public information about the trial results to make more than $134,000 in illegal profits from the purchase and sale of securities in the company, according to a criminal information filed Friday in U.S. District Court in Chicago. Dr. Catenacci purchased more than 8,000 shares before the company Catenacci was the lead clinical investigator on the trial. A day after the acquisition of the shares, he sold them for a profit of more than $134,000. On Dec. 20, 2021, Catenacci entered a partial settlement on the civil charges, paying a civil penalty on the proceeds from the trading. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. A spokesperson for the school said he is on a leave of absence. Find a UChicago Medicine doctor or specialist who's right for you. Search over 1,000 providers by specialty, location, gender and more. |xpg| qfz| zvy| klp| fif| tdc| lvv| sof| hqd| vlq| zme| eyb| sza| zmm| siu| fvv| ifq| isa| zqe| ycz| hwe| yvu| ghf| lgk| kid| qlx| kcr| pau| rqp| hol| rdk| cns| eik| bfx| iqv| kdm| uqb| dbb| obl| twy| lpi| pnv| lkh| yce| emk| abn| rpg| ckm| xxo| drj|